Immunomodulation With Romiplostim in Young Adults With ITP
Status:
Completed
Trial end date:
2020-03-01
Target enrollment:
Participant gender:
Summary
The study aims to investigate immunomodulatory effects of thrombopoietin-receptor Agonist
(TPO-RA) in patients with primary ITP, who failed first-line therapy or who became intolerant
to it. It is hypothesized that the early phase of this autoimmune disease may exhibit a
stronger immunomodulatory potential in response to a stimulus, such as romiplostim. Such a
process may subsequently be capable to induce regulatory mechanisms or tolerance.
Romiplostim (a thrombopoietin-receptor agonist, TPO-RA) will be administered subcutaneously
once weekly over 22 weeks with a starting dose of 1mcg/kg body weight. The dose will be
adjusted based on platelet counts as described in the summary of Product Characteristics
(SmPC).